No Current Confirmation on Morgan Stanley's Sale of Seven Seas Stake

Published 6 hours agoMS

No Current Confirmation on Morgan Stanley's Sale of Seven Seas Stake

Despite speculation, as of May 22, 2025, there is no confirmation that Morgan Stanley is selling its stake in Seven Seas Water to the EQT fund. The most recent transaction involving Seven Seas Water was in March 2020 when Morgan Stanley Infrastructure Partners acquired the company.

Morgan Stanley Infrastructure Partners specializes in investing in crucial infrastructure services, and Seven Seas Water, based in Tampa, Florida, is known for its Water-as-a-Service (WaaS) solutions. This includes outsourced water treatment and wastewater treatment and reuse services provided to a variety of clients. Various sources, such as Business Wire, have detailed these aspects in past reports.

The acquisition strategy by Morgan Stanley highlights their focus on assets that deliver essential public services, which aligns with Seven Seas Water’s role in providing vital water solutions. This transaction remains a significant development as rumors about further sales or changes in ownership are not substantiated by newly available public data.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Intuit Posts Strong Q3 Results and Increases Full-Year Outlook

Intuit Posts Strong Q3 Results and Increases Full-Year Outlook

4 minutes agoINTU

Intuit Inc. delivered robust fiscal third-quarter results, prompting the company to raise its full-year revenue forecast. The Small Business and Self-Employed Group spearheaded growth with a notable 18% rise in revenue, reaching $2.38 billion, as reported by markets.businessinsider.com. This positive performance comes alongside a 19% increase in Online Ecosystem revenues, totaling $1.8 billion, and a 19% boost in QuickBooks Online Accounting revenues to $860 million. Credit Karma, part of Intuit's portfolio, also contributed positively with a 36% increase in revenue to $443 million, driven by strength in credit cards, personal loans, and auto insurance offerings. The company's non-GAAP operating income climbed by 10.5% to $3.71 billion, achieving a non-GAAP operating margin of 55.1%. For the fiscal year 2024, Intuit has raised its revenue forecast to a range of $16.164 billion to $16.2 billion, suggesting a 13% increase. The company anticipates non-GAAP operating income between $6.36 billion and $6.38 billion, with earnings per share expected to fall between $16.79 and $16.84. These updates underline Intuit's robust performance and strategic focus on sustaining growth throughout the year.

Match Group Shakes Up Leadership and Strategy as Challenges Mount

Match Group Shakes Up Leadership and Strategy as Challenges Mount

34 minutes agoMTCH

Match Group, the parent company of the popular dating app Tinder, is undergoing significant leadership changes and strategic shifts to tackle ongoing challenges in the online dating market. Notably, Faye Iosotaluno, who has been spearheading Tinder since early 2024, will step down from her role as CEO in July 2025. Her resignation comes amidst industry-wide hurdles such as declining user engagement and inflation-related pressures. Iosotaluno had focused her efforts on leveraging artificial intelligence to enhance Tinder’s personalization capabilities. Taking the reins will be Spencer Rascoff, co-founder and former CEO of Zillow Group, who will lead Match Group as part of a broader turnaround strategy. Rascoff, who joined Match's board in March 2024, is tasked with revitalizing the company's operations, including overseeing a 13% workforce reduction as a cost-cutting measure. Additionally, under his leadership, Match Group is pursuing the integration of artificial intelligence into its dating platforms, introducing features like a "double date" option and a voice-based flirting game aimed at engaging Gen Z users, as reported by Reuters. Financially, Match Group anticipates its revenue for the second quarter to range between $850 and $860 million, surpassing analyst predictions of $846.7 million despite a 5% drop in paying users during the first quarter. These actions are part of Match Group's strategic efforts to rejuvenate its portfolio in a highly competitive and evolving market landscape.

CPS Technologies Reaches Record 52-Week High Amid Strong Performance

CPS Technologies Reaches Record 52-Week High Amid Strong Performance

49 minutes agoCPSH

CPS Technologies Corporation has achieved a new 52-week high with its stock reaching $2.48 per share. This milestone comes following significant growth and key achievements, including record revenue and profitability in recent quarters. Reuters highlighted that the company reached an intraday high of $2.68, reflecting robust trading activity and investor interest. The company posted a record $7.5 million in revenue for Q1 2025, marking a 27% increase from the previous year. This surge was fueled by strong demand for its AlSiC and hermetic packaging products. Notably, CPS Technologies also returned to profitability with a net income of $0.1 million, overturning a net loss from the same period in 2024. Additionally, operational improvements led to a gross margin of 16.4%, up from 15.3% a year earlier. Strategic initiatives were also bolstered by securing three new Phase I Army SBIR contracts. CPS Technologies' diversified growth strategy has yielded impressive results, as evidenced by its Q1 performance which included record revenue achieved without contributions from its HybridTech Armor® business. These strategic moves and financial improvements demonstrate the company's resilience and adaptability in a competitive market, supporting its recent uptick in stock performance.

FDA Approves GSK's Nucala for COPD Treatment

FDA Approves GSK's Nucala for COPD Treatment

GlaxoSmithKline (GSK) has announced that the U.S. Food and Drug Administration (FDA) granted approval for its drug, Nucala, to be used in treating chronic obstructive pulmonary disease (COPD), also known as 'smoker's lung.' This new approval allows Nucala to be used specifically as an add-on treatment for COPD patients who have an eosinophilic phenotype, characterized by elevated eosinophil levels, which can lead to increased lung inflammation. The approval follows promising results from the MATINEE Phase 3 trial, which showed that adding Nucala to standard inhaled maintenance therapy significantly reduced the annualized rate of moderate or severe exacerbations in patients compared to a placebo over a period of up to 104 weeks. According to Reuters, such advances are substantial considering that approximately 300 million people worldwide are affected by COPD, with an estimated 40% of these cases involving type 2 inflammation. In the competitive landscape, other treatments for COPD include Dupixent from Sanofi and Regeneron, and Ohtuvayre from Verona Pharma. Financially, Nucala has been a strong performer for GSK, with sales growing 18% to reach £1.7 billion in 2023, making up nearly 6% of the company's total sales. This approval is expected to further enhance GSK's position in the COPD market.